

Pipeline behind Marketed OMIDRIA®



Program (Product)	Molecule	Targeted Disease / Procedure	Pre-clinical	Phase 1	Phase 2	Phase 3	FDA Approval	Economic Rights	
<i>Clinical Programs</i>									
MASP-2 / Lectin Pathway (OMS721)	Ab	Stem Cell Transplant-Associated TMA	→						
MASP-2 / Lectin Pathway (OMS721)	Ab	IgA Nephropathy	→						
MASP-2 / Lectin Pathway (OMS721)	Ab	Atypical Hemolytic Uremic Syndrome	→						
MASP-2 / Lectin Pathway (OMS721)	Ab	Lupus Nephritis & Other Renal Diseases	→						
PDE10 (OMS824)	SM	Cognitive Disorders	→						
PPAR γ (OMS405)	SM	Opioid and Nicotine Addiction	→						
PDE7 (OMS527)	SM	Addictions and Compulsive Disorders; Movement Disorders	→						
<i>Preclinical Programs</i>									
MASP-3 / Alternative Pathway (OMS906)	Ab	PNH and a Wide Range of Other Alternative Pathway Disorders	→						
MASP-2, MASP-3, MASP-2/3 and C-1 / Classical Pathway	SM	Disorders of Lectin, Alternative and Classical Pathways of Complement	→						
GPR151, GPR161, GPR174, OPN4	SM	Schizophrenia, Cancer, Sleep Disorders; Photophobia	→						
GPCR Platform	SM	CNS, Metabolic, CV, Oncologic, Musculoskeletal & Other Disorders	→						
Antibody Platform	Ab	Metabolic, CV, Oncologic, Musculoskeletal & Other Disorders	→						

